- Baxter’s $10.5 billion deal for Hill-Rom is a little bit about growing revenue but more about protecting the former’s existing level of health in the face of increasingly powerful hospitals and pressures to cut medical costs.
- Baxter Chief Executive Jose Almeida’s plan is to sell Hill-Rom’s wares to its own more international clientele and cut $250 million of costs a year in the process.
- The two companies’ combined market value on Thursday morning was around $50 billion, pretty much the same as what it was before the share prices started moving in July in anticipation of a merger.
For further details see:
Baxter's $10.5 Billion Deal Is Preventative Medicine